Merrill ups Gilead estimates

Gilead Sciences, Inc. was kept at neutral by Merrill Lynch analyst Eric Ende, who raised 2006 HIV revenue estimates above guidance to $2.11 billion, from $2.04 billion. The analyst also raised his 2006 Tamiflu sales estimate to $2 billion, from $1.4 billion. Gilead reported a strong quarter, with higher revenues offset somewhat by higher research and development spending, according to the analyst. Shares of the Foster City, Calif.-based biopharmaceutical company were up 58 cents, or 0.86%, at $68.30. (Nasdaq: GILD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.